Biology Reference
In-Depth Information
Johner A, Kunz S, Linder M, Shakur Y, Seebeck T (2006) Cyclic nucleotide specific phospho-
diesterases of Leishmania major. BMC Microbiol 6:25
Ke H, Wang H (2007) Crystal structures of phosphodiesterases and implications on substrate
specificity and inhibitor selectivity. Curr Top Med Chem 7:391-403
Kunz S, Kloeckner T, Essen LO, Seebeck T, Boshart M (2004) TbPDE1, a novel class I
phosphodiesterase of Trypanosoma brucei. Eur J Biochem 271:637-647
Kunz S, Oberholzer M, Seebeck T (2005) A FYVE-containing unusual cyclic nucleotide phos-
phodiesterase from Trypanosoma cruzi. FEBS J 272:6412-6422
Kunz S, Beavo JA, D'Angelo MA, Flawia MM, Francis SH, Johner A, Laxman S, Oberholzer M,
Rascon A, Shakur Y, Wentzinger L, Zoraghi R, Seebeck T (2006) Cyclic nucleotide specific
phosphodiesterases of the kinetoplastida: a unified nomenclature. Mol Biochem Parasitol 145:
133-135
Kunz S, Luginbuehl E, Seebeck T (2009a) Gene conversion transfers the GAF-A domain of
phosphodiesterase TbrPDEB1 to one allele of TbrPDEB2 of Trypanosoma brucei. PLoS Negl
Trop Dis 3:e455
Kunz S, Minca M, Luginbuehl E, Bregy P, Seebeck T (2009b) Cyclic nucleotide signaling in the
kinetoplastids. Handbook of cell signaling. Academic Press, New York, NY, pp 1543-1547
Kutateladze TG (2007) Mechanistic similarities in docking of the FYVE and PX domains to
phosphatidylinositol 3-phosphate containing membranes. Prog Lipid Res 46:315-327
Laxman S, Beavo JA (2007) Cyclic nucleotide signaling mechanisms in trypanosomes:Possible
targets for therapeutic agents. Molecular Interventions 7:203-215
Laxman S, Rascon A, Beavo JA (2005) Trypanosome cyclic nucleotide phosphodiesterase 2B
binds cAMP through its GAF-A domain. J Biol Chem 280:3771-3779
Laxman S, Riechers A, Sadilek M, Schwede F, Beavo JA (2006) Hydrolysis products of cAMP
analogs cause transformation of Trypanosoma brucei from slender to stumpy-like forms. Proc
Natl Acad Sci USA 103:19194-19199
Luscher A, Nerima B, Maser P (2006) Combined contribution of TbAT1 and TbMRPA to drug
resistance in Trypanosoma brucei. Mol Biochem Parasitol 150:364-366
Ma P, Wera S, van DP, Thevelein JM (1999) The PDE1-encoded low-affinity phosphodiesterase in
the yeast Saccharomyces cerevisiae has a specific function in controlling agonist-induced
cAMP signaling. Mol Biol Cell 10:91-104
Mancini PE, Patton CL (1981) Cyclic 3
0
,5
0
-adenosine monophosphate levels during the develop-
mental cycle of Trypanosoma brucei brucei in the rat. Mol Biochem Parasitol 3:19-31
McKean PG (2003) Coordination of cell cycle and cytokinesis in Trypanosoma brucei. Curr Opin
Microbiol 6:600-607
Nett IR, Martin DM, Miranda-Saavedra D, Lamont D, Barber JD, Mehlert A, Ferguson MA (2009)
The phosphoproteome of bloodstream form Trypanosoma brucei, causative agent of African
sleeping sickness. Mol Cell Proteomics 8:1527-1538
Oberholzer M, Marti G, Baresic M, Kunz S, Hemphill A, Seebeck T (2007) The Trypanosoma
brucei cAMP phosphodiesterases TbrPDEB1 and TbrPDEB2: flagellar enzymes that are
essential for parasite virulence. FASEB J 21:720-731
Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S (2005) Treatment options
for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.
Lancet Infect Dis 5:763-774
Paine M, Wang M, Boykin D, Wilson W, De Koning H, Olson C, Polig G, Burri C, Brun R,
Murilla G, Thuita JK, Barrett M, Tidwell R (2010) Diamidines for human African trypano-
somiasis. Curr Opin Invest Drugs In Press:
Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, Arnold U, Ghabri S, Baudin E,
Buard V, Kazadi-Kyanza S, Ilunga M, Mutangala W, Pohlig G, Schmid C, Karunakara U,
Torreele E, Kande V (2009) Nifurtimox-eflornithine combination therapy for second-stage
African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III,
non-inferiority trial. Lancet 374:56-64
